Savara Inc.

Savara Inc.

SVRA·NASDAQ

$5.25

+1.9%
HealthcareBiotechnology

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

At a Glance

Live Snapshot
Market Cap$1.08B
EPS-0.5300
P/E Ratio-9.91
Earnings Date08/06/2026

svra

Additional Paid-In Capital

Last Annual Value

811.10M

3-Year CAGR

22%

5-Year CAGR

20%

10-Year CAGR

11%

Savara Inc.

Savara Inc. Competitors Analysis of Additional Paid-In Capital

SVRA · NASDAQ
CompanyAdditional Paid-In Capital
CAGR 3Y
CAGR 5Y
CAGR 10Y
SVRA logo
Savara Inc.
NASDAQ:SVRA
811.10M
15.0%12.8%74.4% 
1.35B
6.4%7.4%28.4%
2.08B
4.1%8.3%6.8%
RZLT logo
Rezolute, Inc.
NASDAQ:RZLT
565.90M
14.5%23.8%26.8%
0.00
N/AN/AN/A
948.97M
15.0%13.4%N/A
0.00
N/AN/AN/A
0.00
N/AN/AN/A
PROK logo
ProKidney Corp.
NASDAQ:PROK
258.55M
92.7%N/AN/A
Savara Inc.

Savara Inc. Fair Value Envelope

SVRA · NASDAQ

Our analysis suggests that SVRA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $5.25, this represents a potential HIDDEN relative to our calculated worth for Savara Inc..

Intrinsic Value
Current Price: $5.25